The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...

Gilead Sciences GILD has outperformed the market over the past 20 years by 3.74% on an annualized basis producing an average ...

The FDA has this on priority review, with a decision expected in August 2024. If approved, this could be a significant addition to Gilead’s portfolio. Johanna Mercier, Gilead’s CCO ...

The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional approval.

Gilead Sciences (GILD – Research Report) received a Buy rating and price target from Wells Fargo analyst Mohit Bansal today. The company’s shares closed last Friday at $84.59. According to ...

“Daina Graybosch has given his Hold rating due to a combination of factors surrounding Gilead Sciences’ prospects with its new drug, lenacapavir.” Daina Graybosch’s assessment of Gilead ...

The drugmaker Gilead Sciences on Wednesday announced a plan to allow six generic pharmaceutical companies in Asia and North ...

Drugmaker Gilead Science announced Thursday that its biannual injections to prevent against HIV had slashed the risk of infection from the virus by a staggering 96 percent. The California ...

The Joint United Nations Programme on HIV/AIDS (UNAIDS) welcomed US-based Gilead Science's announcement of voluntary licensing of its long acting HIV drug lenacapavir for generic production, and asked ...